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ABSTRACT It has been proposed elsewhere [Meeker,
R. B. & Harden, T. K. (1982) Mol. Pharmacol. 22, 310-319]
that muscarinic cholinergic receptor-mediated attenuation of
cAMP accumulation occurs through activation of phosphodi-
esterase in 1321N1 human astrocytoma cells. Pertussis toxin,
which ADP-ribosylates the guanine nucleotide regulatory pro-
tein involved in receptor-mediated inhibition of adenylate cy-
clase (N1), has been utilized to further differentiate between
the mechanism of cholinergic regulation of cAMP metabolism
in 1321N1 cells and the mechanism involving inhibition of ade-
nylate cyclase in other tissues. Muscarinic receptor-mediated
regulation of cAMP accumulation in NG108-15 neuroblasto-
ma-glioma cells occurs through inhibition of adenylate cy-
clase. Pretreatment of these cells with pertussis toxin com-
pletely blocked the capacity of carbachol to attenuate cAMP
accumulation. In contrast, concentrations of pertussis toxin
two to three orders of magnitude higher than those effective in
NG108-15 cells had no effect on muscarinic receptor-mediated
attentuation of cAMP accumulation in 1321N1 cells. In addi-
tion, no effect of pertussis toxin was observed either on the
control rate or the carbachol-stimulated rate of cAMP degra-
dation measured directly in intact 1321N1 cells. A 41,000 Mr
protein previously proposed to be the a subunit of N. was la-
beled during incubation of a plasma membrane fraction from
1321N1 cells with [32P]NAD and pertussis toxin. Pertussis tox-
in is apparently active in 1321N1 cells, since this protein sub-
strate was not labeled in plasma membrane preparations from
cells previously incubated with toxin. Functional activity of N.
was demonstrated by the observation that guanosine 5'-[y
thioltriphosphate- and GTP-mediated inhibition of forskolin-
stimulated adenylate cyclase activity occurred in cell-free
preparations from 1321N1 cells. The inhibitory activity of
these guanine nucleotides was lost in membrane preparations
from pertussis toxin-treated cells. The data suggest that ade-
nylate cyclase is not involved in cholinergic action in 1321N1
cells and, furthermore, N. is not involved in muscarinic recep-
tor-mediated activation of phosphodiesterase in these cells.
Thus, pertussis toxin can be used to differentiate between two
mechanisms of cholinergic regulation of cAMP metabolism.
Activation of muscarinic cholinergic receptors results in at-
tenuation of cAMP accumulation in intact cells and inhibi-
tion of adenylate cyclase activity in cell-free preparations (1-
6). The GTP dependence of this inhibition (4, 5), the negative
heterotropic effects of guanine nucleotides on agonist bind-
ing to inhibitory receptors (6-8), and knowledge of the role
of the stimulatory guanine nucleotide regulatory protein (N,)
in the mechanism of activation of adenylate cyclase (9) have
led to the proposal that an inhibitory guanine nucleotide reg-
ulatory protein (N,) is involved in the mechanism of recep-
tor-mediated inhibition of adenylate cyclase (10). Activation
and inhibition of adenylate cyclase are differentially sensi-
tive to Mn2+ (10), GTP (10-12), and chemical modification
by N-ethylmaleimide (6, 13). Platelets from pseudohypo-
parathyroid patients are functionally deficient in Ns but ex-
press both epinephrine-mediated inhibition of adenylate cy-
clase and GTP-sensitive high-affinity binding of agonists to
a2-adrenergic receptors, suggesting that N1 is fully functional
in these cells (14). Furthermore, cyc- S49 lymphoma cells
lack functional Ns but express active N, (15).
Pertussis toxin, which ADP-ribosylates N1, blocks inhibi-
tory coupling of muscarinic and other receptors to adenylate
cyclase (16, 17). Ns is not a substrate for pertussis toxin (18,
19). Cholera toxin, which ADP-ribosylates Ns (9), does not
ADP-ribosylate N1 (18, 19) and has no effect on receptor-
mediated inhibition of adenylate cyclase (20). Thus, musca-
rinic and other inhibitory receptors regulate adenylate cy-
clase through a guanine nucleotide regulatory protein that is
distinct from the protein involved in regulation of adenylate
cyclase by stimulatory receptors; this inhibitory regulatory
protein can be identified by its susceptibility to modification
by pertussis toxin.
Although muscarinic receptor activation clearly inhibits
adenylate cyclase in cell-free preparations from a variety of
tissues, analyses of cAMP metabolism in 1321N1 astrocyto-
ma cells (21, 22), WI-38 fibroblasts (23, 24), and thyroid
slices (25) have led to the conclusion that muscarinic recep-
tor stimulation also results in activation of phosphodiester-
ase. We have proposed that this is the sole mechanism by
which cAMP levels are reduced in 1321N1 astrocytoma
cells, since, in the presence of phosphodiesterase inhibitors,
cholinergic agonist-mediated decreases in cAMP levels do
not occur, and muscarinic receptor-mediated inhibition of
adenylate cyclase is not detected in membrane preparations
from these cells (21).
One explanation for the mechanism of regulation ofcAMP
metabolism in 1321N1 cells is that muscarinic receptors are
coupled through N1 to activation of phosphodiesterase rather
than inhibition of adenylate cyclase. The occurrence of gua-
nine nucleotide-mediated activation of phosphodiesterase in
several tissues supports this possibility. For example, a well-
characterized GTP regulatory protein, transducin, couples
the light-activated receptor (rhodopsin) of the retinal rod
outer segment to activation of a cGMP phosphodiesterase
(26). On the basis of amino acid composition and electropho-
retic patterns of the proteolyzed polypeptides, transducin,
Ns, and N, appear to be structurally similar guanine nucleo-
tide regulatory proteins (27). A role for a guanine nucleotide
Abbreviations: N, stimulatory guanine nucleotide regulatory pro-
tein; Ni, inhibitory guanine nucleotide regulatory protein; ISO, (-)-
isoproterenol; CARB, carbamoylcholine; PGEI, prostaglandin E1;
GTP[yS], guanosine 5'-[y-thio]triphosphate.
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regulatory protein in the regulation of phosphodiesterase
also is suggested by the reports that guanine nucleotides acti-
vate an insulin-stimulated cAMP phosphodiesterase (28) and
a soluble phosphodiesterase (29) from rat liver. In addition,
de Mazancourt and Guidicelli (30) have reported that a mem-
brane phosphodiesterase from rat brain is stimulated in a
guanine nucleotide-dependent fashion by N6-phenylisopro-
pyladenosine. Interestingly, pertussis toxin ADP-ribosylates
transducin (31, 32) and blocks the light-stimulated hydrolysis
of GTP and cGMP in retinal photoreceptors (31). Elks et al.
(33) also have reported that the insulin-induced activation of
particulate cAMP phosphodiesterase activity in 3T3-L1 adi-
pocytes is blocked by pretreatment of cells with pertussis
toxin.
In this study we have utilized pertussis toxin to further
examine the role of Ni in the muscarinic receptor-mediated
attenuation of cAMP accumulation and activation of phos-
phodiesterase in 1321N1 astrocytoma cells. The results ob-
tained with this cell line are compared to data obtained with
a cell line in which regulation of cAMP levels by muscarinic
receptors apparently occurs through inhibition of adenylate
cyclase. Preliminary reports of this work have been present-
ed (34, 35).
MATERIALS AND METHODS
Dulbecco's modified Eagle's medium, trypsin, fetal calf se-
rum, and defibrinated sheep blood were purchased from
GIBCO. (-)-Isoproterenol [ISO; as the (+)-bitartrate], car-
bamoylcholine (CARB), (+)-propranolol-HCl, cAMP, cre-
atine phosphate, creatine kinase, ATP, GTP, and isobutyl-
methylxanthine were obtained from Sigma. Guanosine 5'-fy-
thio]triphosphate (GTP[yS]) was purchased from Boehringer
Mannheim and forskolin was from Calbiochem. Bordet-
Gengou agar base was purchased from Oxoid (Columbia,
MD) and [2,8-3H]adenine (25-50 Ci/mmol; 1 Ci = 37 GBq)
was from ICN. Affi-Gel blue (100-200 mesh) was obtained
from Bio-Rad and hydroxylapatite was from Calbiochem.
Cell Culture. 1321N1 human astrocytoma cells (21) and
NG108-15 neuroblastoma-glioma cells (36) were grown as
previously described. For pertussis toxin treatment, fresh
medium containing toxin, penicillin (50 units/ml), and strep-
tomycin (50,ug/ml) was transferred to the dishes.
Preparation of Pertussis Toxin. Bordetella pertussis
(strains 165 and Tohama, phase I) was grown for 4 days at
37°C on Bordet-Gengou blood agar plates, harvested, and
inoculated into a small volume of modified Stainer-Scholte
liquid culture medium supplemented with 3% fetal calf se-
rum (37). The cell suspension was maintained in roller bot-
tles at 37°C for 48 hr, diluted 1:100 with serum-free Stainer-
Scholte medium, and shaken for an additional 48 hr. The
cells were removed from the suspension by centrifugation
for 30 min and the supernatant was stored at 4°C. The pertus-
sis supernatant was partially purified by chromatography on
hydroxylapatite according to the method of Yajima et al. (38)
or by chromatography on Affi-Gel blue according to the
method of Sekura et al. (39).
Measurement ofcAMP Accumulation. cAMP accumulation
was monitored as previously described (21). Briefly, 1321N1
cells grown for 7-10 days in 12-well culture dishes (at an ini-
tial seeding density of 40,000 cells per well) or confluent
NG108-15 cells in 12-well dishes (subcultured 2-3 days pre-
viously from a confluent stock plate) were incubated for 1 hr
with 1 ml of Hepes-buffered (20 mM, pH 7.5) Eagle's medi-
um containing [ H]adenine (1-2,uCi/ml for 1321N1 cells and
0.5,Ci/ml for NG108-15 cells). The medium was aspirated,
the cells were washed twice with 1 ml of Hepes/Eagle's me-
dium, and a fresh 0.95-ml aliquot of Hepes/Eagle's medium
was added.[3H~cAMP synthesis was induced by the addition
of 50 Ald of 10uM ISO or 1AuM PGE1, and inhibition of
[3H]cAMP accumulation was measured by the simultaneous
addition of CARB. The reactions proceeded for 10 min and
were terminated by aspiration and the immediate addition of
1 ml of 5% trichloroacetic acid containing 0.5 mM cAMP.
The [3H]cAMP formed during the hormonal challenge was
separated from [3H]ATP by sequential passage over Dowex
and alumina columns as previously described (6). Aliquots of
the cAMP fractions were assayed spectrophotometrically at
259 nm to correct for recovery of cAMP (usually 50-80%).
Preparation of [a-32PJNAD. [a-32P]ATP synthesized by the
method of Johnson and Walseth (40) was used to synthesize
[a-32P]NAD according to the method of Cassel and Pfeuffer
(41). Purity of nucleotides was assessed by chromatography
on polyethyleneimine (PEI)-cellulose (Brinkmann).
[32P]ADP-ribosylation. Preparation of plasma membrane
fractions was as previously described (42). ADP-ribosylation
was carried out at 30'C for 90 min in a final volume of 0.5 ml
containing pertussis toxin (10 Ag of protein), gradient-puri-
fied membranes (120 pug of protein), 10 AM [a-32PJNAD (1-2
Ci/ mmol), 1mM thymidine, 0.5mM ATP, 5mM dithiothrei-
tol, 2.5 mM MgCl2, 6 mM potassium phosphoenolpyruvate,
pyruvate kinase at 10,tg/ml, and 100 mM Tris, pH 8.0. The
reaction was stopped by the addition of 1 ml of ice-cold 50
mM Tris, pH 7.4, and centrifugation at 10,000 x g for 5 min.
The labeled membranes were washed three times by resus-
pension in ice-cold 50 mM Tris, pH 7.4, and centrifugation,
incubated overnight in 100 Al of Laemmli sample buffer (43),
and then applied to a 12.5% sodium dodecyl sulfate discon-
tinuous polyacrylamide gel with a 4% stacking gel. Gels were
fixed; stained with Coomassie brilliant blue, and dried, and
autoradiograms were developed, using Kodak XAR-15 film.
Adenylate Cyclase Assay. Adenylate cyclase activity was
quantitated as previously described (6). Each assay tube
contained (final concentrations) 0.1mM [a-32P]ATP (1.5,uCi
per assay), 1 mM [3H]cAMP (40,000 cpm/assay), 8 mM
phosphocreatine, creatine kinase (6 units per assay), 1 mM
isobutylmethylxanthine, 0.1 mM EGTA, 1.2mM MgC12, 30
mM Tris at pH 8.25, 100 AM forskolin, and various concen-
trations of guanine nucleotides in a final volume of 0.1 ml.
Reactions were started by adding 10-50,g of membrane
protein. The tubes were incubated for 3 min at 30°C and the
reactions were terminated by the addition of 0.9 ml of 5%
trichloroacetic acid. [a-32P]ATP was separated from [32PI-
cAMP by sequential column chromatography over Dowex
and neutral alumina (6). Membrane protein was determined
by the method of Lowry et al. (44).
RESULTS
The activity of pertussis toxin was examined in a cell line
(NG108-15 neuroblastoma-glioma cells) that expresses a
well-characterized muscarinic receptor-linked adenylate cy-
clase system. Concentration-effect curves for CARB-medi-
ated inhibition of cAMP accumulation were generated in
NG108-15 cells pretreated overnight with pertussis toxin or
vehicle (Fig. 1). CARB (100,uM) inhibited PGE,-stimulated
cAMP accumulation by 65% in control cells. Pretreatment
with pertussis toxin enhanced PGE1-stimulated cAMP accu-
mulation. At the high concentration of pertussis toxin,
CARB failed to attenuate PGE1-stimulated cAMP accumula-
tion. In addition, the capacity of epinephrine and morphine
to inhibit cAMP accumulation through a2-adrenergic and
opiate receptors, respectively, was blocked by pretreatment
with pertussis toxin (data not shown). These results are con-
sistent with those previously reported by Kurose et al. (17).
Pretreatment of NG108-15 cells with pertussis toxin also re-
suited in a loss of guanine nucleotide-sensitive binding of the
agonist [3H]oxotremorine-M (45) to muscarinic receptors
without affecting the binding of the antagonist [3 H]quinucli-
dinyl benzilate (data not shown). In contrast to the results
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FIG. 1. Pertussis toxin-induced blockade of muscarinic receptor-
mediated inhibition of cAMP accumulation in NG108-15 cells.
NG108-15 cells were treated overnight with pertussis toxin at 88
ng/ml (o) or 22 ng/ml (o) or with vehicle (A). cAMP accumulation
was measured in the presence of 1 AM PGE1 and the indicated con-
centratiorns ofCARB. The data are plotted as the percent conversion
of [3H]ATP to [3H]cAMP and are the mean of quadruplicate deter-
minations. The data are representative of results from two experi-
ments.
obtained with NG108-15 cells, concentrations of toxin great-
er than two orders of magnitude higher than those maximally
effective in NG108-15 cells had no effect on the capacity of
muscarinic receptors to attenuate ISO-stimulated cAMP ac-
cumulation in 1321N1 cells (Fig. 2).
Since muscarinic receptor activation enhances cAMP deg-
radation in 1321N1 cells (21, 22), the effect of pertussis toxin
on the kinetics of cAMP degradation was examined directly.
cAMP synthesis was stimulated with 10 AM ISO for 10 min.
Propranolol then was added to the cells to block further
cAMP synthesis and the decrease in cAMP levels, which is a
function of phosphodiesterase activity, was measured in the
absence or presence of CARB over the following 3 min. As
we have previously shown (21, 22), the disappearance of
cAMP was a first-order process (Fig. 3). The rate constant
for [3H]cAMP degradation in control cells was 0.46 minm,
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FIG. 2. Differential effects of pertussis toxin on muscarinic re-
ceptor-mediated attenuation of cAMP accumulation in NG108-15
and 1321N1 cells. NG108-15 cells (A) and 1321N1 cells (o) were
preincubated overnight with the indicated concentrations of pertus-
sis toxin. The cells were challenged with 1 IAM PGE1 (NG108-15) or
10 ALM ISO (1321N1) alone or in the presence of 100 /.M CARB. The
results are plotted as the percent inhibition of cAMP accumulation
observed in the presence of CARB. The data are from quadruplicate
determinations and are representative of experiments carried out
with three different preparations of toxin.
80 1
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FIG. 3. Effect of pertussis toxin on cAMP degradation. 1321N1
cells were preincubated overnight in the presence (o, *) or absence
(A, ,) of pertussis toxin (PT) at 100 ng/ml. The cells were then la-
beled with [3H]adenine and [3H]cAMP synthesis was induced with
10 AuM ISO. After 10 min, the synthetic reaction was stopped by the
addition of 50 ul of propranolol (A, o; 10 uM final concentration) or
propranolol (10 /AM, final) + CARB (A, e; 100 AtM final concentra-
tion). The reaction was stopped at the indicated times by aspiration
and addition of 1 ml of 5% trichloroacetic acid containing 0.5 mM
cAMP. The results are plotted as the natural logarithm of the cAMP
concentration at the indicated times (A) divided by the initial cAMP
concentration (AO). The data are representative of results from two
experiments.
= 0.90 min-). cAMP degradation either in the absence (kdcg
= 0.44 mind) or presence (0.82 min') of CARB was not
affected by pretreatment of the cells with pertussis toxin.
Any conclusions from the results presented thus far would
have to be based on the supposition that pertussis toxin was
fully active in intact 1321N1 cells. Experiments were carried
out to examine this possibility. As we have previously re-
ported (42), the presence of Ni in 1321N1 cells is suggested
by the occurrence of a 41,000 Mr substrate for pertussis tox-
in. To confirm that pertussis toxin indeed modified this pro-
tein in intact 1321N1 cells, cells were pretreated with toxin
and lysed, and a membrane fraction was prepared. This frac-
tion then was incubated in the presence of pertussis toxin
and [32PJNAD. As is illustrated in Fig. 4, a 41,000 Mr poly-
peptide was labeled in the presence of pertussis toxin and









FIG. 4. Inhibition of ADP-ribosyla-
tion of the Mr 41,000 protein by prior
treatment of 1321N1 cells with pertus-
sis toxin. 1321N1 cells were treated
with either vehicle (-PT) or with par-
tially purified pertussis toxin at 250
rng/ml (+PT). Plasma membranes were
prepared, incubated with pertussis tox-
in and [a-32P]NAD, and electropho-
resed on 12.5% polyacrylamide gels.
The autoradiogram of the dried gel was
exposed for 72 hr. The positions of
standard proteins of known molecular
weight are shown on the left. Similar
results were obtained in four additional
experiments.
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FIG. 5. Guanine nucleotide-mediated inhibition of forskoli
stimulated adenylate cyclase activity in 1321N1 cells. 1321N1 cells
were incubated overnight in the absence (o, a) or presence (e, A) of
pertussis toxin (100 ng/ml) and lysed, and adenylate cyclase was
assayed for 3 min in the presence of 100 1uM forskolin and the indi-
cated concentrations of GTP or GTP[yS]. The results are plotted as
the percent of adenylate cyclase activity in the absence of guanine
nucleotides and are the mean of quadruplicate determinations. Fors-
kolin-stimulated adepylate cyclase activity in the absence of guanine
nucleotides was 1000 pmol/min per mg and 420 pmol/min per mg for
membranes from control and pertussis toxin-treated cells, respec-
tively. The data are representative of results obtained in two experi-
ments.
ed in membranes prepared from cells previously treated with
toxin. This result is consistent with the idea that pertussis
toxin ADP-ribosylates Ni in intact 1321N1 cells.
The presence of a 41,000 Mr substrate for pertussis toxin
in 1321N1 cells does not necessarily prove the presence of
functional N.. Indeed, the lack of muscarinic receptor-medi-
ated inhibition of adenylate cyclase in spite of the presence
of muscarinic receptors and adenylate cyclase could be ex-
plained by the absence of N, or its presence in a functionally
altered form. Seamon and Daly (46) have presented data sup-
porting the idea that inhibition of forskolin-stimulated ade-
nylate cyclase activity by guanine nucleotides provides a
measure of the functional activity of N;. That is, since fors-
kolin "maximally" activates adenylate cyclase, the stimula-
tory effects ofguanine nucleotides are not observed in the
presence of forskolin, and, thus, the inhibitory effects of
these nucleotides mediated through N; become apparent. As
illustrated in Fig. 5, both GTP and GTP[yS] inhibited forsko-
lin-stimulated adenylate cyclase activity in 1321N1 mem-
branes. The values for the half-maximal effect for each of the
nucleotides were similar to those observed in membranes
from other tissues (15, 36). In contrast to cohtrol mem-
branes, neither guanine nucleotide inhibited (in fact, a stimu-
lation was observed) adenylate cyclase in membranes from
pertussis toxin-pretreated cells. In addition to blockade of
the inhibitory effects of guanine nucleotides, pertussis toxin
pretreatment resulted in a decrease in forskolin-stimulated
activity measured in the absence of a guanine nucleotide.
DISCUSSION
Earlier work by this laboratory (21, 22) led to the proposal
that activation of muscarinic cholinergic receptors in 1321N1
cells reduces cAMP levels by activating phosphodiesterase:
(i) the time necessary to attain maximal cAMP levels is re-
duced in the presence of a muscarinic receptor agonist; (it)
inhibitors of phosphodiesterase noncompetitively block the
inhibitory effect of muscarinic receptors on cAMP accumu-
lation; (iii) muscarinic receptor agonists increase the rate of
cAMP degradation assessed directly in intact cells; (iv) the
Ca2+ ionophore A23187 mimics the effects of muscarinic re-
ceptor agonists, and in the absence of extracellular Ca2' the
effects of muscarinic receptor stimulation are lost; (v) al-
though muscarinic receptor-mediated inhibition of adenylate
cyclase occurs in broken cell preparations from other cell
types, no evidence for inhibition has been obtained in ho-
mogenates of 1321N1 cells.
The current work withpertussis toxin adds further support
to the idea that a mechanism not involving adenylate cyclase
is responsible for muscarinic receptor-mediated reduction in
cAMP levels in 1321N1 cells. The functional presence of Ni
is apparently necessary for the occurrence of receptor or
guanine nucleotide-mediated inhibition of adenylate cyclase;
pertussis toxin ADP-ribosylates and functionally inactivates
N.. Thus, the lack of an effect of pertussis toxin on musca-
rinic receptor-mediated attenuation of cAMP accumulation
is further proof of the hypothesis that cholinergic regulation
of cAMP metabolism in 1321N1 cells occurs through phos-
phodiesterase rather than adenylate cyclase.
The work has additional ramifications. There is ample
precedent regarding a role for a guanine nucleotide-binding
protein in the regulation of phosphodiesterase. Studies sug-
gesting such an involvement have ranged from thewell-char-
acterized retinal rhodopsin-phosphodiesterase system, in
which transducin serves an obligatory coupling function (26,
31), to the less well-understood recent findings suggesting
regulation of liverphosphodiesterase by GTP (28, 29). It re-
cently has been reported that pertussis toxin ADP-ribosy-
lates and modifies the function of transducin (31, 32) and that
pertussis toxin blocks the insulin-induced activation ofpar-
ticulate phosphodiesterase activity in 3T3 adipocytes (33).
Thus, not only is there precedent for a role of a guanine nu-
cleotide regulatory protein in the regulation of phosphodies-
terase activity, but pertussis toxin has been utilized to modi-
fy these activities. In spite of these levels at which N, might
subserve a role in 1321N1 cells, the complete lack of an ef-
fect of very high concentrations of pertussis toxin relative to
those effective in NG108-15 cells suggests that Ni is not in-
volved in muscarinic receptor-mediated activation of phos-
phodiesterase.
Although there is no reason to believe that the 41,000 Mr
substrate for pertussis toxin in 1321N1 membranes is not the
pertussis toxin substrate observed by others in a variety of
tissues, we cannot with absolute confidence conclude that
this protein is Ni that is fully functional in all regards. None-
theless, the fact that guanine nucleotides inhibit forskolin-
stimulated adenylate cyclase activity is consistent with the
idea that the interface between Ni and the other components
of the adenylate cyclase system is normal in 1321N1 cells. A
functionally relevant interaction between Ni and muscarinic
receptors in 1321N1 cells has not been identified. Perhaps
our failure to observe muscarinic receptor-mediated inhibi-
tion of adenylate cyclase is due to failure to identify optimal
assay conditions; alternatively, a mnuscarinic receptor-linked
adenylate cyclase activity could become "uncoupled" upon
cell lysis and membrane preparation. Our prejudice, howev-
er, is that neither of these possibilities is responsible for fail-
ure to observe cholinergic regulation of adenylate cyclase.
The complete reversal of muscarinic receptor-mediated at-
tenuation of cAMP accumulation by phosphodiesterase in-
hibitors, as well as the extent of the enhancement of cAMP
degradation in the presence of cholinergic agonists, indicates
that muscarinic receptor-mediated activation of phosphodi-
esterase can fully accourit for the attenuation of cAMP accu-
mulation.
A possible explanation for the data obtained with 1321N1
cells is that a muscarinic receptor subtype exists on these
cells that is incapable of coupling through Ni to regulate ade-
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have been proposed to exist (47). It is logical to propose that
these receptor subtypes would be coupled to different bio-
chemical mechanisms; the two most likely mechanisms
would involve adenylate cyclase and Ca2' mobilization. We
have recently shown that muscarinic receptor activation in
1321N1 cells causes a marked increase in phosphoinositide
breakdown and unidirectional efflux of 45Ca2+ from 45Ca2 -
prelabeled cells (48). Thus, 1321N1 cells may express a mus-
carinic receptor subtype that is different from that on
NG108-15 cells and is incapable of coupling to Ni. In this
regard, radioligand binding studies examining the affinities
of the purportedly muscarinic receptor-selective antagonist
pirenzepine and a series of agorlists have revealed differ-
ences in the relative drug selectivity of the muscarinic recep-
tor populations of 1321N1 versus NG108-15 cells (49).
In summary, although examples of a role for a guanine
nucleotide regulatory protein in the regulation of phosphodi-
esterase are available, we have been unable to confirm the
involvement of such a protein in the mechanism of muscarin-
ic receptor regulation of phosphodiesterase in 1321N1 cells.
Obviously, this conclusion relies on the activity of pertussis
toxin in blocking any involvement of Ni in the cholinergic
regulation of phosphodiesterase. Thus, N, could be involved
in some unknown pertussis toxin-insensitive mechanism.
However, in light of other findings with pertussis toxin re-
garding transducin and Ni, the most parsimonious interpreta-
tion of the results is that Ni is not involved in muscarinic
receptor-mediated activation of phosphodiesterase and that
two separate mechanisms whereby muscarinic receptors at-
tenuate cAMP accumulation can be differentiated on the ba-
sis of their susceptibility to inactivation by pertussis toxin.
In light of the recent report by Gomperts (50), the possibility
that an unknown guanine nucleotide regulatory protein plays
a role in coupling muscarinic receptors to mobilization of
Ca2+ and activation of phosphodiesterase cannot be discount-
ed on the basis of this work.
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